{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:26:10Z","timestamp":1793755570529,"version":"4.6.1"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,23]],"date-time":"2020-03-23T00:00:00Z","timestamp":1584921600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,3,23]],"date-time":"2020-03-23T00:00:00Z","timestamp":1584921600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017596","name":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte","doi-asserted-by":"crossref","award":["V-16703\/68502\/2016-2020"],"award-info":[{"award-number":["V-16703\/68502\/2016-2020"]}],"id":[{"id":"10.13039\/100017596","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Universit\u00e4tsklinikum Bonn","award":["V-16703\/68502\/2016-2020"],"award-info":[{"award-number":["V-16703\/68502\/2016-2020"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Older adults are more prone to develop adverse drug reactions (ADRs) since they exhibit numerous risk factors. The first aim was to analyse the number of spontaneous ADR reports regarding older adults (&gt;\u200965) in the ADR database of the German Federal Institute for Drugs and Medical Devices (BfArM) and to set them in relation to i) the number of ADR reports concerning younger adults (19\u201365), and ii) the number of inhabitants and assumed drug-exposed inhabitants. The second aim was to analyse, if reported characteristics occurred more often in older vs. younger adults.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>All spontaneous ADR reports involving older or younger adults within the period 01\/01\/2000\u201310\/31\/2017 were identified in the ADR database. Ratios concerning the number of ADR reports\/number of inhabitants and ADR reports\/drug-exposed inhabitants were calculated. The reports for older (<jats:italic>n<\/jats:italic>\u2009=\u200969,914) and younger adults (<jats:italic>n<\/jats:italic>\u2009=\u2009111,463) were compared using descriptive and inferential statistics.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The absolute number of ADR reports involving older adults increased from 1615 (2000) up to 5367 ADR reports (2016). The age groups 76\u201384 and 70\u201379 had the highest number of ADR reports with 25 ADR reports per 100,000 inhabitants and 27 ADR reports per 100,000 assumed drug-exposed inhabitants. For both ratios, the number of reports was higher for males (26 and 28 ADR reports) than for females (24 and 26 ADR reports). Fatal outcome was reported almost three times more often in older vs. younger adults. Six out of ten drug substances most frequently suspected were antithrombotics (vs. 1\/10 in younger adults). For some drug substances (e.g. rivaroxaban) the ADRs reported most frequently differed between older (epistaxis) and younger adults (menorrhagia).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>There is a need to further investigate ADRs in older adults since they occurred more frequently in older vs. younger adults and will likely increase in future. Physicians should be aware of different ADRs being attributed to the same drug substances which may be more prominent in older adults. Regular monitoring of older adults taking antithrombotics is recommended.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40360-020-0392-9","type":"journal-article","created":{"date-parts":[[2020,3,23]],"date-time":"2020-03-23T16:05:06Z","timestamp":1584979506000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Adverse drug reactions in older adults: a retrospective comparative analysis of spontaneous reports to the German Federal Institute for Drugs and Medical Devices"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8763-051X","authenticated-orcid":false,"given":"Diana","family":"Dubrall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja S.","family":"Just","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia C.","family":"Stingl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhardt","family":"Sachs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,23]]},"reference":[{"key":"392_CR1","volume-title":"Hazzard's geriatric medicine & gerontology","author":"JB Halter","year":"2009","unstructured":"Halter JB, Ouslander JG, Tinetti ME, Studenski S, High KP, Asthana S. Hazzard's geriatric medicine & gerontology. 6th ed. New York: McGraw-Hill; 2009.","edition":"6"},{"issue":"4","key":"392_CR2","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1111\/bcp.12596","volume":"80","author":"EA Davies","year":"2015","unstructured":"Davies EA, O'Mahony MS. Adverse drug reactions in special populations \u2013 the elderly. Br J Clin Pharmacol. 2015;80(4):796\u2013807.","journal-title":"Br J Clin Pharmacol"},{"key":"392_CR3","unstructured":"Robert Koch-Institut (Hrsg). Daten und Fakten: Ergebnisse der Studie \u00bbGesundheit in Deutschland aktuell 2012\u00ab. Beitr\u00e4ge zur Gesundheitsberichterstattung des Bundes. RKI, Berlin. 2014. ."},{"key":"392_CR4","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1007\/s00103-013-1667-8","volume":"56","author":"H Knopf","year":"2013","unstructured":"Knopf H, Grams D. Arzneimittelanwendung von Erwachsenen in Deutschland. Ergebnisse der Studie zur Gesundheit Erwachsener in Deutschland (DEGS1). Bundesgesundheitsbl. 2013;56:868\u201377.","journal-title":"Bundesgesundheitsbl"},{"issue":"8","key":"392_CR5","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/S0531-5565(03)00133-5","volume":"38","author":"K Turnheim","year":"2003","unstructured":"Turnheim K. When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly. Exp Gerontol. 2003;38(8):843\u201353.","journal-title":"Exp Gerontol"},{"issue":"12","key":"392_CR6","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1007\/BF03262002","volume":"35","author":"L Aagaard","year":"2012","unstructured":"Aagaard L, Strandell J, Melskens L, Petersen PS, Holme HE. Global patterns of adverse drug reactions over a decade: analyses of spontaneous reports to VigiBase\u2122. Drug Saf. 2012;35(12):1171\u201382.","journal-title":"Drug Saf"},{"issue":"2","key":"392_CR7","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1046\/j.1365-2125.2003.01875.x","volume":"57","author":"PA Routledge","year":"2004","unstructured":"Routledge PA, O'Mahony MS, Woodhouse KW. Adverse drug reactions in elderly patients. Br J Clin Pharmacol. 2004;57(2):121\u20136.","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"392_CR8","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/BF03261973","volume":"35","author":"C Wu","year":"2012","unstructured":"Wu C, Bell CM, Wodchis WP. Incidence and economic burden of adverse drug reactions among elderly patients in Ontario emergency departments: a retrospective study. Drug Saf. 2012;35(9):769\u201381.","journal-title":"Drug Saf"},{"issue":"4","key":"392_CR9","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s00228-002-0467-0","volume":"58","author":"S Schneeweiss","year":"2002","unstructured":"Schneeweiss S, Hasford J, G\u00f6ttler M, Hoffmann A, Riethling AK, Avorn J. Admissions caused by adverse drug events to internal medicine and emergency departments in hospitals: a longitudinal population-based study. Eur J Clin Pharmacol. 2002;58(4):285\u201391.","journal-title":"Eur J Clin Pharmacol"},{"key":"392_CR10","first-page":"251","volume":"115","author":"AM Schurig","year":"2018","unstructured":"Schurig AM, B\u00f6hme M, Just KS, Scholl C, Dormann H, Plank-Kiegele B, et al. Adverse drug reactions (ADR) and emergencies. The prevalence of suspected ADR in four emergency departments in Germany. Dtsch Arztebl Int. 2018;115:251\u20138.","journal-title":"Dtsch Arztebl Int"},{"issue":"2","key":"392_CR11","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/pds.1263","volume":"16","author":"K Wester","year":"2007","unstructured":"Wester K, J\u00f6nsson A, Spigset O, H\u00e4gg S. Spontaneously reported fatal suspected adverse drug reactions: a 10-year survey from Sweden. Pharmacoepidemiol Drug Saf. 2007;16(2):173\u201380.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"392_CR12","unstructured":"Statistisches Bundesamt. Bev\u00f6lkerungspyramide. https:\/\/service.destatis.de\/bevoelkerungspyramide\/#!y=2020. Accessed 2019."},{"key":"392_CR13","unstructured":"Statistisches Bundesamt. Bev\u00f6lkerung Deutschlands bis 2060\u201313. koordinierte Bev\u00f6lkerungsvorausberechnung. https:\/\/www.destatis.de\/DE\/Themen\/Gesellschaft-Umwelt\/Bevoelkerung\/Bevoelkerungsvorausberechnung\/Publikationen\/Downloads-Vorausberechnung\/bevoelkerung-deutschland-2060-presse-5124204159004.pdf?__blob=publicationFile. Accessed Apr 2015."},{"issue":"1","key":"392_CR14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1177\/2042098615615472","volume":"7","author":"AH Lavan","year":"2016","unstructured":"Lavan AH, Gallagher P. Predicting risk of adverse drug reactions in older adults. Ther Adv Drug Saf. 2016;7(1):11\u201322.","journal-title":"Ther Adv Drug Saf"},{"issue":"8619","key":"392_CR15","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/S0140-6736(88)90100-6","volume":"332","author":"G Hopf","year":"1988","unstructured":"Hopf G, Mathias B. Adverse reactions reporting and age. Lancet. 1988;332(8619):1079\u201380.","journal-title":"Lancet"},{"issue":"8610","key":"392_CR16","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/S0140-6736(88)92713-4","volume":"332","author":"L Ann Tanner","year":"1988","unstructured":"Ann Tanner L, Baum C. Spontaneous adverse reaction reporting in the elderly. Lancet. 1988;332(8610):580.","journal-title":"Lancet"},{"issue":"3","key":"392_CR17","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/pds.4155","volume":"26","author":"L Holm","year":"2017","unstructured":"Holm L, Ekman E, Jors\u00e4ter BK. Influence of age, sex and seriousness on reporting of adverse drug reactions in Sweden. Pharmacoepidemiol Drug Saf. 2017;26(3):335\u201343.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"31\u201332","key":"392_CR18","first-page":"543","volume":"107","author":"S Holt","year":"2010","unstructured":"Holt S, Schmiedl S, Th\u00fcrmann PA. Potentially inappropriate medications in the elderly: the PRISCUS list. Dtsch Arztebl Int. 2010;107(31\u201332):543\u201351.","journal-title":"Dtsch Arztebl Int"},{"issue":"4","key":"392_CR19","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/jgs.15767","volume":"67","author":"DM Fick","year":"2019","unstructured":"Fick DM, Semla TP, Beizer J, et al. American Geriatrics Society 2019 updated beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019;67(4):674\u201394.","journal-title":"J Am Geriatr Soc"},{"issue":"2","key":"392_CR20","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s40266-013-0146-0","volume":"31","author":"AM Kuhn-Thiel","year":"2014","unstructured":"Kuhn-Thiel AM, Weib C, Wehling M. Consensus validation of the FORTA (fit fOR the aged) list: a clinical tool for increasing the appropriateness of pharmacotherapy in the elderly. Drugs Aging. 2014;31(2):131\u201340.","journal-title":"Drugs Aging"},{"issue":"1","key":"392_CR21","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1006\/phrs.1998.0483","volume":"40","author":"P Cutroneo","year":"1999","unstructured":"Cutroneo P, Greco S, Cucinotta G, Arcoraci V, Caputi AP. Spontaneous reporting of adverse drug reactions in elderly patients in sicily (Italy). Pharmacol Res. 1999;40(1):41\u20136.","journal-title":"Pharmacol Res"},{"key":"392_CR22","unstructured":"Federal Institute for Drugs and Medical Devices (BfArM). https:\/\/www.bfarm.de\/EN\/Home\/home_node.html."},{"key":"392_CR23","unstructured":"Statistische Bundesamt. GENESIS-online. https:\/\/www-genesis.destatis.de\/genesis\/online\/logon?language=en. Accessed 2019."},{"key":"392_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-662-54630-7","volume-title":"Arzneiverordnungsreport 2017","author":"U Schwabe","year":"2017","unstructured":"Schwabe U, Paffrath D, Ludwig WD, Klauber J. Arzneiverordnungsreport 2017. Berlin Heidelberg: Springer Verlag Berlin-Heidelberg; 2017."},{"issue":"23","key":"392_CR25","first-page":"393","volume":"115","author":"D Dubrall","year":"2018","unstructured":"Dubrall D, Schmid M, Ale\u0161ik E, Paeschke N, Stingl J, Sachs B. Frequent adverse drug reactions, and medication groups under suspicion. Dtsch Arztebl Int. 2018;115(23):393\u2013400.","journal-title":"Dtsch Arztebl Int"},{"key":"392_CR26","unstructured":"European Medicines Agency. National competent authorities (human). https:\/\/www.ema.europa.eu\/en\/partners-networks\/eu-partners\/eu-member-states\/national-competent-authorities-human."},{"key":"392_CR27","unstructured":"Federal Institute for Drugs and Medical Devices and Paul-Ehrlich-Institut. Online reporting of side effects. https:\/\/nebenwirkungen.pei.de\/nw\/EN\/home\/home_node.html;jsessionid=BD6D021E6F2104BDA8C8469E09C246BC.2_cid319."},{"key":"392_CR28","unstructured":"European Medicines Agency. EudraVigilance - European database of suspected adverse drug reaction reports. http:\/\/www.adrreports.eu\/en\/index.html."},{"key":"392_CR29","unstructured":"Federal Institute for Drugs and Medical Devices. European Database on Adverse Drug Reaction Reports. https:\/\/www.bfarm.de\/EN\/Drugs\/vigilance\/ReportingRisks\/uawDB\/_node.html;jsessionid=3AA69F0B3C9EFE14A8A1605332865F3D.1_cid354."},{"key":"392_CR30","unstructured":"European Medicines Agency. EudraVigilance. https:\/\/www.ema.europa.eu\/en\/human-regulatory\/researchdevelopment\/pharmacovigilance\/eudravigilance\/access-eudravigilance-data."},{"key":"392_CR31","unstructured":"European Medicines Agency. Access to EudraVigilance data. https:\/\/www.ema.europa.eu\/en\/human-regulatory\/research-development\/pharmacovigilance\/eudravigilance\/access-eudravigilance-data. Accessed 2 Mar 2017."},{"key":"392_CR32","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology. Anatomical Therapeutical Chemical (ATC) Classification. https:\/\/www.whocc.no\/atc_ddd_index\/. Accessed 13 Dec 2018."},{"key":"392_CR33","unstructured":"German Institute of Medical Documentation and Information (DIMDI). ATC-Classification. https:\/\/www.dimdi.de\/dynamic\/en\/drugs\/atc-classification\/index.html."},{"key":"392_CR34","unstructured":"MedDRA: Medical Dictionary for Regulatory Activities. Introductory Guide MedDRA Version 22.1. https:\/\/www.meddra.org\/sites\/default\/files\/guidance\/file\/000354_intguide_22.1.pdf. Accessed Sept 2019."},{"key":"392_CR35","unstructured":"DIRECTIVE 2001\/83\/EC of the European parliament and of the Council. https:\/\/ec.europa.eu\/health\/sites\/health\/files\/files\/eudralex\/vol-1\/dir_2001_83_consol_2012\/dir_2001_83_cons_2012_en.pdf. Accessed 16 Nov 2012."},{"key":"392_CR36","unstructured":"European Medicines Agency. Guidline on good pharmacovigilance practices (GVP): Annex I - Definitions (Rev 4). https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-good-pharmacovigilance-practices-annex-i-definitions-rev-4_en.pdf. Accessed 9 Oct 2017."},{"key":"392_CR37","unstructured":"World Health Organization. Health statistics and information systems: Proposed working definition of an older person in Africa for the MSD Project. https:\/\/www.who.int\/healthinfo\/survey\/ageingdefnolder\/."},{"key":"392_CR38","unstructured":"RDocumentation. Random Samples and Permutations. https:\/\/www.rdocumentation.org\/packages\/base\/versions\/3.6.1\/topics\/sample."},{"issue":"1","key":"392_CR39","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s40264-013-0131-x","volume":"37","author":"T Bergvall","year":"2014","unstructured":"Bergvall T, Noren GN, Lindquist M. vigiGrade: a tool to identify well-documented individual case reports and highlight systematic data quality issues. Drug Saf. 2014;37(1):65\u201377.","journal-title":"Drug Saf"},{"issue":"9237","key":"392_CR40","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","volume":"356","author":"R Edwards","year":"2000","unstructured":"Edwards R, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356(9237):1255\u20139.","journal-title":"Lancet"},{"issue":"3","key":"392_CR41","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/pds.4726","volume":"28","author":"B Sachs","year":"2019","unstructured":"Sachs B, Dubrall D, Fischer-Barth W, Schmid M, Stingl J. Drug-induced anaphylactic reactions in children: a retrospective analysis of 159 validated spontaneous reports. Pharmacoepidemiol Drug Saf. 2019;28(3):377\u201388.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"392_CR42","unstructured":"Medicinal Products Act (Arzneimittelgesetz \u2013 AMG). Medicinal Products Act in the version published on 12 December 2005 (Federal Law Gazette [BGBl.]) Part I p. 3394, last amended by Article 11 of the Act of 6 May 2019 (Federal Law Gazette I p. 646). https:\/\/www.gesetze-iminternet.de\/englisch_amg\/englisch_amg.pdf. Accessed 6 May 2019."},{"issue":"1","key":"392_CR43","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s40801-015-0054-1","volume":"3","author":"G Ozcan","year":"2016","unstructured":"Ozcan G, Aykac E, Kasap Y, Nemutlu NT, Sen E, Aydinkarahaliloglu ND. Adverse drug reaction reporting pattern in Turkey: analysis of the National Database in the context of the first Pharmacovigilance legislation. Drugs Real World Outcomes. 2016;3(1):33\u201343.","journal-title":"Drugs Real World Outcomes"},{"issue":"8","key":"392_CR44","doi-asserted-by":"publisher","first-page":"731","DOI":"10.2165\/00002018-200528080-00007","volume":"28","author":"F Thiessard","year":"2005","unstructured":"Thiessard F, Roux E, Miremont-Salam\u00e9 G, Fourrier-R\u00e9glat A, Haramburu F, Tubert-Bitter P, et al. Trends in spontaneous adverse drug reaction reports to the French pharmacovigilance system (1986-2001). Drug Saf. 2005;28(8):731\u201340.","journal-title":"Drug Saf"},{"issue":"13","key":"392_CR45","first-page":"213","volume":"110","author":"H Dormann","year":"2013","unstructured":"Dormann H, Sonst A, M\u00fcller F, Vigler R, Patapovas A, Pfistermeister B, et al. Adverse drug events in older patients admitted as an emergency-the role of potentially inappropriate medication in elderly people (PRISCUS). Dtsch Arztebl Int. 2013;110(13):213\u20139.","journal-title":"Dtsch Arztebl Int"},{"issue":"6","key":"392_CR46","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1002\/pds.2118","volume":"20","author":"D Rottenkolber","year":"2011","unstructured":"Rottenkolber D, Schmiedl S, Rottenkolber M, Farker K, Salj\u00e9 K, Mueller S, et al. Adverse drug reactions in Germany: direct costs of internal medicine hospitalizations. Pharmacoepidemiol Drug Saf. 2011;20(6):626\u201334.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"392_CR47","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1046\/j.1365-2125.2002.01690.x","volume":"54","author":"B B\u00e9gaud","year":"2002","unstructured":"B\u00e9gaud B, Martin K, Fourrier A, Haramburu F. Does age increase the risk of adverse drug reactions? Br J Clin Pharmacol. 2002;54(5):550\u20132.","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"392_CR48","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1177\/009127009803801103","volume":"38","author":"C Tran","year":"1998","unstructured":"Tran C, Knowles SR, Liu BA, Shear NH. Gender differences in adverse drug reactions. J Clin Pharmacol. 1998;38(11):1003\u20139.","journal-title":"J Clin Pharmacol"},{"key":"392_CR49","doi-asserted-by":"publisher","first-page":"100188","DOI":"10.1016\/j.eclinm.2019.10.001","volume":"17","author":"S Watson","year":"2019","unstructured":"Watson S, Caster O, Rochon PA, den Ruijter H. Reported adverse drug reactions in women and men: aggregated evidence from globally collected individual case reports during half a century. EClinicalMedicine. 2019;17:100188.","journal-title":"EClinicalMedicine"},{"issue":"3","key":"392_CR50","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2165\/00003088-200948030-00001","volume":"48","author":"OP Soldin","year":"2009","unstructured":"Soldin OP, Mattison DR. Sex differences in pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2009;48(3):143\u201357.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"392_CR51","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2165\/00128071-200102060-00001","volume":"2","author":"M Rademaker","year":"2001","unstructured":"Rademaker M. Do women have more adverse drug reactions? Am J Clin Dermatol. 2001;2(6):349\u201351.","journal-title":"Am J Clin Dermatol"},{"key":"392_CR52","unstructured":"Statistisches Bundesamt. Deaths, life expectancy. https:\/\/www.destatis.de\/EN\/FactsFigures\/SocietyState\/Population\/Deaths\/Deaths.html."},{"key":"392_CR53","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s00228-008-0494-6","volume":"64","author":"Y Zopf","year":"2008","unstructured":"Zopf Y, Rabe C, Neubert A, Ga\u00dfmann KG, Rascher W, Hahn EG, et al. Women encounter ADRs more often than do men. Eur J Clin Pharmacol. 2008;64:999\u20131004.","journal-title":"Eur J Clin Pharmacol"},{"key":"392_CR54","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1046\/j.1472-8206.2002.00100.x","volume":"16","author":"JL Montastruc","year":"2002","unstructured":"Montastruc JL, Lapeyre-Mestre M, Bagheri H, Fooladi A. Gender differences in adverse drug reactions: analysis of spontaneous reports to a regional Pharmacovigilance Centre in France. Fundam Clin Pharmacol. 2002;16:343\u20136.","journal-title":"Fundam Clin Pharmacol"},{"key":"392_CR55","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/pds.2630010105","volume":"1","author":"RD Mann","year":"1992","unstructured":"Mann RD, Rawlins MD, Fletcher P, Wood SM. Age and the spontaneous reporting of adverse reactions in the United Kingdom. Pharmacoepidemiol Drug Saf. 1992;1:19\u201323.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"9","key":"392_CR56","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/S0895-4356(02)00450-X","volume":"55","author":"J Hasford","year":"2002","unstructured":"Hasford J, Goettler M, Munter KH, M\u00fcller-Oberlinghausen B. Physicians\u2019 knowledge and attitudes regarding the spontaneous reporting system for adverse drug reactions. J Clin Epidemiol. 2002;55(9):945\u201350.","journal-title":"J Clin Epidemiol"},{"issue":"9","key":"392_CR57","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1007\/s00228-014-1707-9","volume":"70","author":"F Montastruc","year":"2014","unstructured":"Montastruc F, Duguet C, Rousseau V, Bagheri H, Montastruc JL. Potentially inappropriate medications and adverse drug reactions in the elderly: a study in a PharmacoVigilance database. Eur J Clin Pharmacol. 2014;70(9):1123\u20137.","journal-title":"Eur J Clin Pharmacol"},{"issue":"21","key":"392_CR58","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1056\/NEJMsa1103053","volume":"365","author":"DS Budnitz","year":"2011","unstructured":"Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. 2011;365(21):2002\u201312.","journal-title":"N Engl J Med"},{"key":"392_CR59","doi-asserted-by":"crossref","unstructured":"Greil W, H\u00e4berle A, Schuhmann T, Grohmann R, Baumann P. Age and adverse drug reactions from psychopharmacological treatment: data from the AMSP drug surveillance programme in Switzerland. Swiss Med Wkly. 2013;143:w13772.","DOI":"10.4414\/smw.2013.13772"},{"issue":"24","key":"392_CR60","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1001\/jama.2018.8194","volume":"319","author":"V Selak","year":"2018","unstructured":"Selak V, Kerr A, Poppe K, Wu P, Harwood M, Grey C, et al. Annual risk of major bleeding among persons without cardiovascular disease not receiving antiplatelet therapy. JAMA. 2018;319(24):2507\u201320.","journal-title":"JAMA"},{"issue":"9","key":"392_CR61","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.7150\/ijms.34629","volume":"16","author":"K Shimada","year":"2019","unstructured":"Shimada K, Hasegawa S, Nakao S, Mukai R, Sasaoka S, Ueda N, et al. Adverse reaction profiles of hemorrhagic adverse reactions caused by direct oral anticoagulants analyzed using the Food and Drug Administration adverse event reporting system (FAERS) database and the Japanese adverse drug event report (JADER) database. Int J Med Sci. 2019;16(9):1295\u2013303.","journal-title":"Int J Med Sci"},{"issue":"9198","key":"392_CR62","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/S0140-6736(99)06457-0","volume":"355","author":"A Fugh-Berman","year":"2000","unstructured":"Fugh-Berman A. Herb-drug interactions. Lancet. 2000;355(9198):134\u20138.","journal-title":"Lancet"},{"key":"392_CR63","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.euroneuro.2005.04.007","volume":"15","author":"S von Campenhausen","year":"2005","unstructured":"von Campenhausen S, Bornschein B, Wick R, B\u00f6tzel K, Sampaio C, Poewe W, et al. Prevalence and incidence of Parkinson\u2019s disease in Europe. Eur Neuropsychopharmacol. 2005;15:473\u201390.","journal-title":"Eur Neuropsychopharmacol"},{"key":"392_CR64","volume-title":"The second fifty years: promoting health and preventing disability","year":"1992","unstructured":"Berg RL, Cassels JS, editors. The second fifty years: promoting health and preventing disability. Washington (DC): National Academies Press; 1992."},{"issue":"21","key":"392_CR65","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1001\/archinternmed.2009.357","volume":"169","author":"JC Woolcott","year":"2009","unstructured":"Woolcott JC, Richardson KJ, Wiens MO, Patel B, Marin J, Khan KM, et al. Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Arch Intern Med. 2009;169(21):1952\u201360.","journal-title":"Arch Intern Med"},{"issue":"4","key":"392_CR66","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1111\/bcp.13876","volume":"85","author":"R Ruiter","year":"2019","unstructured":"Ruiter R, Burggraaf J, Rissmann R. Under-representation of elderly in clinical trials: an analysis of the initial approval documents in the Food and Drug Administration database. Br J Clin Pharmacol. 2019;85(4):838\u201344.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"392_CR67","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","volume":"29","author":"L Hazell","year":"2006","unstructured":"Hazell L, Shakir SA. Under-reporting of adverse drug reactions. Drug Saf. 2006;29(5):385\u201396.","journal-title":"Drug Saf"},{"issue":"20","key":"392_CR68","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3310\/hta15200","volume":"15","author":"AJ Avery","year":"2011","unstructured":"Avery AJ, Anderson C, Bond CM, Fortnum H, Gifford A, Hannaford PC, et al. Evaluation of patient reporting of adverse drug reactions to the UK \u2018yellow card scheme\u2019: literature review, descriptive and qualitative analyses, and questionnaire surveys. Health Technol Assess. 2011;15(20):23\u201332.","journal-title":"Health Technol Assess"},{"issue":"1","key":"392_CR69","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1046\/j.1365-2125.2001.01306.x","volume":"51","author":"CF Green","year":"2001","unstructured":"Green CF, Mottram DR, Rowe PH, Pirmohamed M. Attitudes and knowledge of hospital pharmacists to adverse drug reaction reporting. Br J Clin Pharmacol. 2001;51(1):81\u20136.","journal-title":"Br J Clin Pharmacol"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-020-0392-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40360-020-0392-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-020-0392-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T00:12:37Z","timestamp":1616458357000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-020-0392-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,23]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["392"],"URL":"https:\/\/doi.org\/10.1186\/s40360-020-0392-9","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,23]]},"assertion":[{"value":"14 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study had been approved by the local ethics committee of the Medical Faculty of Bonn (009\/17).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"25"}}